Medical countermeasures against henipaviruses: a review and public health perspective.
Animals
COVID-19
/ prevention & control
Chiroptera
/ virology
Clinical Trials, Phase III as Topic
Disease Outbreaks
/ prevention & control
Henipavirus
/ classification
Henipavirus Infections
/ drug therapy
Humans
Medical Countermeasures
Nipah Virus
/ pathogenicity
Public Health
SARS-CoV-2
/ pathogenicity
Journal
The Lancet. Infectious diseases
ISSN: 1474-4457
Titre abrégé: Lancet Infect Dis
Pays: United States
ID NLM: 101130150
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
30
04
2021
revised:
02
07
2021
accepted:
02
07
2021
pubmed:
5
11
2021
medline:
5
1
2022
entrez:
4
11
2021
Statut:
ppublish
Résumé
Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific medical countermeasures to control infections in humans. We review the evidence of medical countermeasures against henipaviruses and project their cost in a post-COVID-19 era. Given the sporadic and unpredictable nature of henipavirus outbreaks, innovative strategies will be needed to circumvent the infeasibility of traditional phase 3 clinical trial regulatory pathways. Stronger partnerships with scientific institutions and regulatory authorities in low-income and middle-income countries can inform coordination of appropriate investments and development of strategies and normative guidelines for the deployment and equitable use of multiple medical countermeasures. Accessible measures should include global, regional, and endemic in-country stockpiles of reasonably priced small molecules, monoclonal antibodies, and vaccines as part of a combined collection of products that could help to control henipavirus outbreaks and prevent future pandemics.
Identifiants
pubmed: 34735799
pii: S1473-3099(21)00400-X
doi: 10.1016/S1473-3099(21)00400-X
pmc: PMC8694750
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13-e27Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests NT is an independent consultant to the Coalition for Epidemic Preparedness Innovations (CEPI). All other authors are employees of CEPI. CEPI is supporting the research and development of a diverse portfolio of vaccine candidates (including vaccines against Nipah virus) based on a range of vaccine approaches.
Références
Nat Struct Mol Biol. 2019 Oct;26(10):980-987
pubmed: 31570878
Vaccine. 2015 Jun 4;33(24):2823-9
pubmed: 25865472
Vaccines (Basel). 2020 Mar 02;8(1):
pubmed: 32131403
J Virol. 2009 Nov;83(22):11979-82
pubmed: 19759137
N Engl J Med. 2021 Jan 21;384(3):289-291
pubmed: 33471984
NPJ Vaccines. 2017 Aug 8;2:21
pubmed: 29263876
N Engl J Med. 2019 May 9;380(19):1804-1814
pubmed: 31067370
N Engl J Med. 2020 May 21;382(21):1969-1973
pubmed: 32227757
PLoS Pathog. 2010 Nov 11;6(11):e1001186
pubmed: 21085610
J Virol. 2014 May;88(9):4624-31
pubmed: 24522928
Antiviral Res. 2020 Mar;175:104712
pubmed: 31935422
Viruses. 2019 Dec 24;12(1):
pubmed: 31878180
Vaccine X. 2019 Jul 15;2:100034
pubmed: 31428741
Ann Neurol. 2002 Jun;51(6):703-8
pubmed: 12112075
Vaccine. 2016 Sep 14;34(40):4777-86
pubmed: 27544586
NPJ Vaccines. 2018 Oct 5;3:42
pubmed: 30323953
Vaccine. 2011 Aug 5;29(34):5623-30
pubmed: 21689706
Sci Transl Med. 2011 Oct 19;3(105):105ra103
pubmed: 22013123
Antiviral Res. 2017 Aug;144:147-152
pubmed: 28629988
PLoS Pathog. 2009 Oct;5(10):e1000642
pubmed: 19888339
J Infect Dis. 2019 May 24;219(12):1867-1878
pubmed: 30364984
Emerg Infect Dis. 2013 Feb;19(2):210-7
pubmed: 23347678
mBio. 2015 Mar 10;6(2):e02427
pubmed: 25759505
Ann Neurol. 2001 Jun;49(6):810-3
pubmed: 11409437
Med J Armed Forces India. 2020 Oct;76(4):370-376
pubmed: 32895599
J Virol. 2009 May;83(10):5148-55
pubmed: 19264786
Front Microbiol. 2019 Mar 11;10:418
pubmed: 30915049
NPJ Vaccines. 2019 Apr 15;4:15
pubmed: 31016033
PLoS One. 2011 Apr 06;6(4):e18437
pubmed: 21494680
Emerg Infect Dis. 2014 Mar;20(3):372-9
pubmed: 24572697
J Infect Dis. 2020 May 11;221(Suppl 4):S471-S479
pubmed: 31686101
J Pediatric Infect Dis Soc. 2021 May 28;10(5):629-634
pubmed: 33388760
Essays Biochem. 2016 Jun 30;60(1):111-20
pubmed: 27365041
Front Immunol. 2020 Apr 09;11:592
pubmed: 32373111
N Engl J Med. 2010 Jun 10;362(23):2166-74
pubmed: 20558367
Vaccine. 2010 Dec 16;29(2):212-20
pubmed: 21050901
J Virol. 2011 Mar;85(5):2004-11
pubmed: 21177820
J Infect. 2019 Jun;78(6):491-503
pubmed: 30851290
J Infect Dis. 2013 Feb 1;207(3):469-78
pubmed: 23175762
J Virol Methods. 2009 Sep;160(1-2):1-6
pubmed: 19559943
Emerg Infect Dis. 2019 Jun;25(6):1144-1152
pubmed: 31107231
Virol J. 2013 Dec 13;10:353
pubmed: 24330654
Vaccine. 2021 Sep 15;39(39):5600-5606
pubmed: 34426025
Trop Med Infect Dis. 2021 Feb 14;6(1):
pubmed: 33672796
PLoS Negl Trop Dis. 2019 Jun 6;13(6):e0007462
pubmed: 31170144
Virology. 2002 Apr 25;296(1):190-200
pubmed: 12036330
J Virol. 2017 Feb 28;91(6):
pubmed: 28077641
Am J Public Health. 2014 Nov;104(11):e85-91
pubmed: 25211753
J Virol. 2006 Aug;80(16):7929-38
pubmed: 16873250
NPJ Vaccines. 2016 Jul 28;1:16003
pubmed: 29263849
Viruses. 2020 Apr 23;12(4):
pubmed: 32340278
BMJ Glob Health. 2019 Feb 1;4(Suppl 2):e001118
pubmed: 30815286
Sci Transl Med. 2014 Jun 25;6(242):242ra82
pubmed: 24964990
J Virol. 2012 Nov;86(21):11457-71
pubmed: 22915804
Antimicrob Agents Chemother. 2006 May;50(5):1768-72
pubmed: 16641448
J Virol. 2006 Dec;80(24):12293-302
pubmed: 17005664
J Infect Dis. 2020 May 11;221(Suppl 4):S359-S362
pubmed: 32392321
Sci Transl Med. 2012 Aug 8;4(146):146ra107
pubmed: 22875827
Vaccine. 2014 May 7;32(22):2637-44
pubmed: 24631094
NPJ Vaccines. 2020 Jun 15;5(1):51
pubmed: 32566261
Antiviral Res. 2014 Jan;101:26-9
pubmed: 24184127
Vaccine. 2008 Jul 23;26(31):3842-52
pubmed: 18556094
Vet Pathol. 2010 Sep;47(5):774-8
pubmed: 20551476
Front Immunol. 2020 Jun 11;11:842
pubmed: 32595632
Sci Rep. 2018 May 15;8(1):7604
pubmed: 29765101
PLoS Pathog. 2010 Oct 28;6(10):e1001168
pubmed: 21060819
Sheng Wu Gong Cheng Xue Bao. 2006 May;22(3):418-24
pubmed: 16755921
PLoS One. 2013;8(3):e58414
pubmed: 23516477
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
Vet Microbiol. 2020 Feb;241:108549
pubmed: 31928698
Virol J. 2009 Nov 04;6:187
pubmed: 19889218
Cell. 2020 Dec 10;183(6):1536-1550.e17
pubmed: 33306954
NPJ Vaccines. 2021 Feb 8;6(1):23
pubmed: 33558494
J Virol. 2004 Jan;78(2):834-40
pubmed: 14694115
Aust Vet J. 2018 May;96(5):161-166
pubmed: 29691855
Int Rev Immunol. 2017 Mar 4;36(2):108-121
pubmed: 28060559
NPJ Vaccines. 2016;1:
pubmed: 28706736
J Virol. 2006 Feb;80(4):1972-8
pubmed: 16439553
PLoS Negl Trop Dis. 2019 Dec 12;13(12):e0007419
pubmed: 31830030
NPJ Vaccines. 2016 Aug 25;1:16013
pubmed: 29263855
Lancet Infect Dis. 2020 Apr;20(4):445-454
pubmed: 32027842
J Infect Dis. 2018 May 18;217(suppl_1):S48-S55
pubmed: 29788339
J Infect Dis. 2020 May 11;221(Supplement_4):S480-S492
pubmed: 32037447
Assay Drug Dev Technol. 2014 Apr;12(3):155-61
pubmed: 24735442
Immunity. 2013 Jan 24;38(1):92-105
pubmed: 23273844
Virology. 2012 Oct 25;432(2):327-35
pubmed: 22726244
Emerg Microbes Infect. 2019;8(1):272-281
pubmed: 30866781
J Infect Dis. 2018 Jun 20;218(2):218-227
pubmed: 29566184
J Virol. 2015 Jan;89(1):144-54
pubmed: 25320306
J Infect Dis. 2020 May 11;221(Suppl 4):S493-S498
pubmed: 31751453
Vet Microbiol. 2019 Oct;237:108405
pubmed: 31561922
J Virol. 2015 Dec 16;90(5):2372-87
pubmed: 26676770
Virol J. 2013 Jul 16;10:237
pubmed: 23867060
J Prev Med Public Health. 2017 Mar;50(2):91-99
pubmed: 28372353
Ann N Y Acad Sci. 2006 Oct;1081:243-5
pubmed: 17135518
Epidemiol Infect. 2020 Apr 23;148:e90
pubmed: 32321607
Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10652-7
pubmed: 15998730
J Gen Virol. 2010 Mar;91(Pt 3):765-72
pubmed: 19889926